All In Biotech

Drug Trial Radar · NCT03327402

Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

A Phase 1 Open-label Study of the Safety, Tolerability, and Pharmacokinetics of d- and l-Amphetamine After Multiple Daily Doses of SHP465 6.25 mg Administered in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder

Last checked: Nov 19, 2026Latest source record: Jun 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Mar 13, 2018

Primary completion

Oct 5, 2018

Study completion Oct 5, 2018

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Oct 31, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years, up to 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of SHP465 in children aged 4 to 5 years with ADHD after multiple daily doses of 6.25 milligram (mg) SHP465

Conditions

  • Attention Deficit Hyperactivity Disorder (ADHD)

Interventions

  • SHP465Drug

    SHP465 capsule will be administered at a dose of 6.25 mg, orally once daily for 4 weeks. SHP465 is comprised of sulfate salts of dextroamphetamine and amphetamine, with dextroamphetamine saccharate and amphetamine aspartate monohydrate, which provide a composite enantiomer ratio of 3:1 d-amphetamine to l-amphetamine.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Plasma Drug Concentration (Cmax) Occurred at the Time of Maximum Observed Concentration Sampled During a Dosing Interval (Tmax) of Plasma Dextroamphetamine (d-Amphetamine) and Plasma Levoamphetamine (l-Amphetamine)Time frame: Week 4: Predose, 2, 5, 8, 12, 16, 24 hours (Day 8), 48 hours (Day 9) Postdose on Day 7
  2. Trough Plasma Drug Concentration Ctrough at Steady State (Ctrough,ss) of Plasma d-Amphetamine and Plasma l-AmphetamineTime frame: Predose on Day 1 and Day 28 and at 24 hours (Day 29) postdose on Day 28
  3. Time to Reach Maximum Observed Plasma Drug Concentration (Tmax) During Dosing Interval of Plasma d-Amphetamine and Plasma l-AmphetamineTime frame: Week 4: Predose, 2, 5, 8, 12, 16, 24 hours (Day 8), 48 hours (Day 9) Postdose on Day 7
  4. Area Under the Concentration-Time Curve From Time Zero to the Last Timepoint (AUC0-t) During Sample Collection of Plasma d-Amphetamine and Plasma l-AmphetamineTime frame: Week 4: Predose, 2, 5, 8, 12, 16, 24 hours (Day 8), 48 hours (Day 9) Postdose on Day 7
  5. Area Under the Concentration-Time Curve From Time Zero Predose to Five Hours Postdose (AUC0-5) of Plasma d-Amphetamine and Plasma l-AmphetamineTime frame: Week 4: Predose, 2, 5 hours Postdose on Day 7
  6. Area Under the Concentration Time Curve From Time Five Hours to the Last Timepoint (AUC5-t) of Plasma d-Amphetamine and Plasma l-AmphetamineTime frame: Week 4: 5, 8, 12, 16, 24 hours (Day 8), 48 hours (Day 9) Postdose on Day 7
  7. Area Under the Concentration-Time Curve From Time of Dosing to the Last Measurable Concentration (AUClast) of Plasma d-Amphetamine and Plasma l-AmphetamineTime frame: Week 4: Predose, 2, 5, 8, 12, 16, 24 hours (Day 8), 48 hours (Day 9) Postdose on Day 7
  8. Area Under the Concentration-Time Curve Over the Dosing Interval (24 Hours) at Steady State (AUCtau,ss) of Plasma d-Amphetamine and Plasma l-AmphetamineTime frame: Week 4: Predose, 2, 5, 8, 12, 16, 24 hours (Day 8), 48 hours (Day 9) Postdose on Day 7
  9. Terminal Rate Constant (Lambda z) of Plasma d-Amphetamine and Plasma l-AmphetamineTime frame: Week 4: Predose, 2, 5, 8, 12, 16, 24 hours (Day 8), 48 hours (Day 9) Postdose on Day 7
  10. Total Body Clearance (CL/F) for Extravascular Administration of Plasma d-Amphetamine and Plasma l-AmphetamineTime frame: Week 4: Predose, 2, 5, 8, 12, 16, 24 hours (Day 8), 48 hours (Day 9) Postdose on Day 7
  11. Terminal Half-life (t1/2) of Plasma d-Amphetamine and Plasma l-AmphetamineTime frame: Week 4: Predose, 2, 5, 8, 12, 16, 24 hours (Day 8), 48 hours (Day 9) Postdose on Day 7
  12. Apparent Volume of Distribution (Vss/F) at Steady State of Plasma d-Amphetamine and Plasma l-AmphetamineTime frame: Week 4: Predose, 2, 5, 8, 12, 16, 24 hours (Day 8), 48 hours (Day 9) Postdose on Day 7
  13. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From start of study drug administration up to follow-up (up to 5 weeks)
  14. Number of Participants With Clinically Significant Changes in Vital Signs Reported as TEAEsTime frame: From start of study drug administration up to follow-up (up to 5 weeks)
  15. Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Reported as TEAEsTime frame: From start of study drug administration up to follow-up (up to 5 weeks)
  16. Change From Baseline in Height at Final On-Treatment AssessmentTime frame: FoTA (up to Day 30)
  17. Change From Baseline in Weight at Final On-Treatment AssessmentTime frame: FoTA (up to Day 30)
  18. Number of Participants With Clinically Significant Changes in Clinical Laboratory Results Reported as TEAEsTime frame: From start of study drug administration up to follow-up (up to 5 weeks)
  19. Number of Participants With Overall Quality of Sleep Assessed by Post Sleep Questionnaire (PSQ) at Final On-Treatment AssessmentTime frame: FoTA (up to Day 30)
  20. Length of Time Awake Per Night Assessed by PSQ at Final On-Treatment AssessmentTime frame: FoTA (up to Day 30)
  21. Length of Time to Fall Asleep Per Night Assessed by PSQ at Final On-Treatment AssessmentTime frame: FoTA (up to Day 30)
  22. Length of Time Sleeping Per Night Assessed by PSQ at Final On-Treatment AssessmentTime frame: FoTA (up to Day 30)
  23. Total Sleep Disturbance Score of Children's Sleep Habits Questionnaire (CSHQ ) at Final On-Treatment AssessmentTime frame: FoTA (up to Day 30)
  24. Number of Participants With a Positive Response in Columbia-Suicide Severity Rating Scale (C-SSRS) at Final On-Treatment AssessmentTime frame: FoTA (up to Day 30)

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Preferred Research Partners

    Little Rock, Arkansas

  • Clinical Neuroscience Solutions Inc

    Orlando, Florida

  • Qualmedica Research, LLC

    Evansville, Indiana

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Ohio Pediatric Research Assn Inc

    Dayton, Ohio

  • Professional Psychiatric Services (PPS)

    Mason, Ohio

  • Coastal Pediatric Associates

    Mt. Pleasant, South Carolina

  • Clinical Neuroscience Solutions Inc

    Memphis, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.